Qynapse to present clinical results of QyScore® for Alzheimer’s Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

QYNAPSE today announced it will present clinical data on QyScore® for Alzheimer’s disease and multiple sclerosis at the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 - 22, 2021. Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation on June 20, 2021, at 6:05 a.m. ET and Philippe Tran, R&D Scientist at Qynapse, will give an ePoster on June 20, 2021, at 1:30 p.m. ET.

Qynapse reaffirms its commitment to research in Multiple Sclerosis and is pleased to announce new projects to advance research and clinical care for MS patients

Qynapse joins the global multiple sclerosis (MS) community in recognition of World MS Day to raise awareness for everyone affected by MS. Emphasizing the World MS Day 2021 theme, MS Connections, Qynapse has been engaged for years in contributing to connect MS patients to MS research, especially in the field of neuroimaging innovation.

QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Qynapse joins Decentralized Trials & Research Alliance (DTRA) to democratize and accelerate clinical trials

QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

QYNAPSE to sponsor and exhibit at the 106th RSNA Annual Meeting and present its latest AI-neuroimaging advancements, which are transforming care for patients with brain disorders

QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.

QYNAPSE appoints Matt Ullum as Chief Commercial Officer to drive and accelerate its growth globally

QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.